Design Therapeutics Inc. (NASDAQ: DSGN)
$4.55
+0.0650 ( +1.45% ) 213.1K
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
Market Data
Open
$4.55
Previous close
$4.48
Volume
213.1K
Market cap
$257.05M
Day range
$4.28 - $4.71
52 week range
$1.94 - $8.31
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 14 | Nov 13, 2023 |
10-q | Quarterly Reports | 65 | Nov 13, 2023 |
4 | Insider transactions | 1 | Oct 02, 2023 |
4/a | Other | 1 | Sep 06, 2023 |
4 | Insider transactions | 1 | Sep 05, 2023 |
4 | Insider transactions | 1 | Aug 30, 2023 |
4 | Insider transactions | 1 | Aug 30, 2023 |
8-k | 8K-related | 12 | Aug 25, 2023 |
10-q | Quarterly Reports | 64 | Aug 14, 2023 |
8-k | 8K-related | 14 | Aug 14, 2023 |